Literature DB >> 12448837

Membrane Na(+)-K+ ATPase mediated cascade in bipolar mood disorder, major depressive disorder, and schizophrenia--relationship to hemispheric dominance.

A Ravi Kumar Kurup1, P A Kurup.   

Abstract

The isoprenoid pathway produces digoxin, an endogenous membrane Na(+)-K+ ATPase inhibitor and regulator of neurotransmitter transport. The objective of the study was to relate digoxin status and hemispheric dominance to the pathogenesis of psychiatric disorders--bipolar mood disorder, major depressive disorder, and schizophrenia. The following parameters were assessed in bipolar mood disorder during the manic phase and depressive phase of the illness as well as in major depressive disorder, and schizophrenia: HMG CoA reductase activity, tryptophan and tyrosine catabolic patterns, red blood cell (RBC) Na(+)-K+ ATPase activity, and serum magnesium. These parameters were compared to individuals of differing hemispheric dominance. The levels of serum digoxin and HMG CoA reductase activity were found to be decreased in the depressive phase of bipolar mood disorder and major depressive disorder with a corresponding increase in RBC Na(+)-K+ ATPase activity and serum magnesium levels. There was increase in tyrosine and tyrosine catabolites, and a reduction in tryptophan and its catabolites, in the serum in the depressive phase of bipolar mood disorder and major depressive disorder. The neurotransmitter patterns and digoxin levels in the depressive phase of bipolar mood disorder/major depressive disorder correlated with those in right-handed/left hemisphere dominant individual. The neurotransmitter patterns and digoxin levels in the manic phase of bipolar mood disorder and schizophrenia correlated with those in left-handed/right hemisphere dominant individuals. Digoxin status and hemispheric dominance could correlate with the pathogenesis of psychiatric disorders--schizophrenia, major depressive disorder, and bipolar mood disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12448837     DOI: 10.1080/00207450290025978

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  10 in total

1.  MK-801 alters Na+, K+-ATPase activity and oxidative status in zebrafish brain: reversal by antipsychotic drugs.

Authors:  Kelly Juliana Seibt; Renata da Luz Oliveira; Denis Broock Rosemberg; Luiz Eduardo Baggio Savio; Emilene B S Scherer; Felipe Schmitz; Angela T S Wyse; Carla Denise Bonan
Journal:  J Neural Transm (Vienna)       Date:  2011-12-06       Impact factor: 3.575

2.  Alterations on Na⁺,K⁺-ATPase and acetylcholinesterase activities induced by amyloid-β peptide in rat brain and GM1 ganglioside neuroprotective action.

Authors:  Fernando Kreutz; Emilene B Scherer; Andréa G K Ferreira; Fernanda Dos Santos Petry; Camila Lino Pereira; Fabiana Santana; Angela Terezinha de Souza Wyse; Christianne Gazzana Salbego; Vera Maria Treis Trindade
Journal:  Neurochem Res       Date:  2013-09-08       Impact factor: 3.996

3.  Chronic Treatment with a Clinically Relevant Dose of Methylphenidate Increases Glutamate Levels in Cerebrospinal Fluid and Impairs Glutamatergic Homeostasis in Prefrontal Cortex of Juvenile Rats.

Authors:  Felipe Schmitz; Paula Pierozan; André F Rodrigues; Helena Biasibetti; Daniella M Coelho; Ben Hur Mussulini; Mery S L Pereira; Mariana M Parisi; Florencia Barbé-Tuana; Diogo L de Oliveira; Carmen R Vargas; Angela T S Wyse
Journal:  Mol Neurobiol       Date:  2015-05-24       Impact factor: 5.590

4.  Mild hyperhomocysteinemia reduces the activity and immunocontent, but does not alter the gene expression, of catalytic α subunits of cerebral Na+,K+-ATPase.

Authors:  Emilene B S Scherer; Samanta O Loureiro; Fernanda C Vuaden; Felipe Schmitz; Janaína Kolling; Cassiana Siebert; Luiz Eduardo B Savio; Bruna M Schweinberger; Maurício R Bogo; Carla D Bonan; Angela T S Wyse
Journal:  Mol Cell Biochem       Date:  2013-03-07       Impact factor: 3.396

5.  Methylphenidate Decreases ATP Levels and Impairs Glutamate Uptake and Na+,K+-ATPase Activity in Juvenile Rat Hippocampus.

Authors:  Felipe Schmitz; Paula Pierozan; André F Rodrigues; Helena Biasibetti; Mateus Grings; Bruna Zanotto; Daniella M Coelho; Carmen R Vargas; Guilhian Leipnitz; Angela T S Wyse
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

6.  Severe Hyperhomocysteinemia Decreases Respiratory Enzyme and Na(+)-K(+) ATPase Activities, and Leads to Mitochondrial Alterations in Rat Amygdala.

Authors:  Janaína Kolling; Emilene B S Scherer; Cassiana Siebert; Aline Longoni; Samanta Loureiro; Simone Weis; Letícia Petenuzzo; Angela T S Wyse
Journal:  Neurotox Res       Date:  2015-12-22       Impact factor: 3.911

7.  Methylphenidate treatment increases Na(+), K (+)-ATPase activity in the cerebrum of young and adult rats.

Authors:  Emilene B S Scherer; Cristiane Matté; Andréa G K Ferreira; Karin M Gomes; Clarissa M Comim; Cristiane Mattos; João Quevedo; Emilio L Streck; Angela T S Wyse
Journal:  J Neural Transm (Vienna)       Date:  2009-09-12       Impact factor: 3.575

8.  Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain.

Authors:  Tiago P Freitas; Giselli Scaini; Cristiane Corrêa; Patricia M Santos; Gabriela K Ferreira; Gislaine T Rezin; Morgana Moretti; Samira S Valvassori; João Quevedo; Emilio L Streck
Journal:  J Neural Transm (Vienna)       Date:  2010-02       Impact factor: 3.575

9.  Na+,K+-ATPase activity in an animal model of mania.

Authors:  Alexandra I Zugno; Samira S Valvassori; Emilene B S Scherer; Cristiane Mattos; Cristiane Matté; Camila L Ferreira; Gislaine T Rezin; Angela T S Wyse; João Quevedo; Emilio L Streck
Journal:  J Neural Transm (Vienna)       Date:  2009-03-03       Impact factor: 3.575

10.  Validation of the animal model of bipolar disorder induced by Ouabain: face, construct and predictive perspectives.

Authors:  Samira S Valvassori; Gustavo C Dal-Pont; Wilson R Resende; Roger B Varela; Jéssica Lopes-Borges; José Henrique Cararo; João Quevedo
Journal:  Transl Psychiatry       Date:  2019-06-04       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.